Clinical trials: PPA
Healthy Subjects
Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin
- Trial name
- NCT03643575
- Testing
- Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Strength Chest Congestion, Organ-I- NR tablet
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Healthy Subjects
Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h
Demonstrate bioequivalence of guaifenesin in Mucinex® extended release (ER) 600 mg tablet in normal healthy volunteers compared to the immediate release guaifenesin 200 mg tablet reference product marketed
- Trial name
- NCT03642262
- Testing
- Mucinex®
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Healthy Subjects
Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin and hydrocodone bitartrate when they are administered alone or in combination to normal healthy male and/or female subjects.
- Trial name
- NCT03642873
- Testing
- Humibid®, Hydrocodone Bitartrate, Humibid® and Hydrocodone Bitartrate tablet
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy Subjects
Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions
- Trial name
- NCT03649750
- Testing
- Mucinex®
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC
Healthy Subjects
Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
This was an open label, multicentric, non-comparative, single arm prospective post marketing surveillance (PMS) study to evaluate the safety and tolerability of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID…
- Trial name
- NCT03725085
- Testing
- Mucinex™ extended-release (SE)
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Healthy Subjects
Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers
Determine bioequivalence, safety and tolerability of guaifenesin extended-release 600 mg (Mucinex® SE) compared to an immediate-release syrup reference product in normal healthy subjects.
- Trial name
- NCT03644095
- Testing
- Mucinex® SE, Vicks Cough Syrup for Chesty Coughs
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Alzheimer's Disease, Frontotemporal Dementia, Behavioral Variant
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NetCogBs (NCT03422250)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Caregivers Burnout, Frontotemporal Dementia
Support Via Technology: Living and Learning With Advancing FTD
Much effort over the last several decades has been devoted to developing and implementing psychoeducational interventions for family caregiving partners for those with Alzheimer's and relatedm dementias (ADRD).
- Trial name
- STELLA-FTD (NCT05338710)
- Testing
- STELLA-FTD
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD)
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies
- Trial name
- NCT02676843
- Testing
- 18F-AV-1451
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer's Disease, Frontotemporal Dementia
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease…
- Trial name
- NCT01890343
- Testing
- florbetapir 18F, 18F-FDG
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across…
- Trial name
- NCT03706261
- Testing
- 18F-MK-6240, 18F-Florbetaben
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Adam Brickman
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers
Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects
- Trial name
- NCT03644108
- Testing
- Mucinex® ER 600 mg
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Frontotemporal Dementia, Behavioral Variant
Intranasal Insulin in Frontotemporal Dementia (FTD)
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the…
- Trial name
- NCT04115384
- Testing
- Novolin-R insulin
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Depression, Stress, Psychological
Rural Dementia Caregiver Project
Rural caregivers face challenges of geographic isolation and lower health care access and quality. Many rural dementia caregivers experience serious health consequences due to caregiving responsibilities that can limit their…
- Conditions
- Depression, Stress, Psychological, Self Efficacy, Loneliness
- Trial name
- NCT04428112
- Testing
- Building Better Caregivers Workshop, Attention Control
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dementia, Alzheimer's Disease
In-Home Technology for Dementia Caregivers
This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal…
- Conditions
- Dementia, Alzheimer's Disease, Frontotemporal Dementia
- Trial name
- NCT03828383
- Testing
- In-home technology, Limited in-home technology
- Where
- 5 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Dementia, Cognitive Dysfunction
A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
Despite well-documented disparities in Alzheimer's disease and related dementia (AD) prevalence, incidence, treatment, and mortality, individuals from disadvantaged backgrounds (e.g.
- Conditions
- Dementia, Cognitive Dysfunction, Alzheimer Disease, Lewy Body Disease
- Trial name
- NCT05444244
- Testing
- Relational Research Recruitment and Engagement Intervention
- Where
- United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet
Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet
- Trial name
- NCT03633487
- Testing
- Mucinex®
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC